The up and down roller coaster ride for shares of Predictive Technology Group Inc (OTCMKTS:PRED) continues into this week, with the stock sliding back under the buck threshold to close out last week. To add some color to the story, the company just announced that it has engaged with LifeSci Partners to increase awareness of the company’s brand and clinical programs.
According to the release, “LifeSci is a leading provider of strategic consulting services in the areas of investor relations, public relations, corporate communications, executive search and capital markets advisory. LifeSci Advisors, LLC and LifeSci Public Relations will provide Predictive with integrated communications services through strategic messaging, investor and media outreach, social and digital media efforts.”
Predictive Technology Group Inc (OTCMKTS:PRED) promulgates itself as a company that, together with its subsidiaries, develops and commercializes discoveries and technologies involved in novel molecular diagnostic and pharmaceutical therapeutic/human cells, tissues, and human cellular and tissue-based products (HCT/Ps).
The company operates through two segments, Regenerative Medicine Products and HCT/Ps, and Diagnostics and Therapeutics. It offers ARTguide, a genetic diagnostic and prognostic test for women experiencing infertility as a result of endometriosis and other health concerns; and regenerative medicine products, including AmnioCyteT, AmnioCyte PlusT, PolyCyteT, and CoreCyteT.
The company was formerly known as Global Enterprises Group, Inc. and changed its name to Predictive Technology Group, Inc. in July 2015. Predictive Technology Group, Inc. was founded in 2005 and is headquartered in Salt Lake City, Utah.
According to company materials, “Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively.”
Find out when $PRED reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As noted above, PRED just announced that it has engaged with LifeSci Partners to increase awareness of the company’s brand and clinical programs.
While this is a clear factor, it has been incorporated into a trading tape characterized by a pretty dominant offer, which hasn’t been the type of action PRED shareholders really want to see. In total, over the past five days, shares of the stock have dropped by roughly -28% on above average trading volume.
All in all, not a particularly friendly tape, but one that may ultimately present some new opportunities. What’s more, the listing has seen a growing influx of trading interest, with the stock’s recent average trading volume running just under 160% above its longer-run average levels.
“We are excited to work with LifeSci to inform the public and the investment community about our innovative data analytics that help physicians identify and combat diseases using our unique treatments and therapeutics,” said Bradley C. Robinson, president and chief executive officer of Predictive. “LifeSci’s expertise in investor relations and public relations, as well as their decades of experience in capital markets, media relations and scientific research have made them the perfect communications partner for our company as we work to grow our business and reach new audiences.”
Currently trading at a market capitalization of $267M, PRED has a reserve ($1.8M) of cash on the books, which compares with about $14.1M in total current liabilities. One should also note that debt has been growing over recent quarters. PRED is pulling in trailing 12-month revenues of $43.5M. In addition, the company is seeing major top-line growth, with y/y quarterly revenues growing at 88%. This is an exciting story, and we look forward to a follow-up chapter as events transpire. Sign-up for continuing coverage on shares of $PRED stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $PRED, either long or short, and we have not been compensated for this article.